A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | August 2014 |
| End Date: | July 9, 2016 |
A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
The purpose of this study is to isolate and measure circulating tumor cells in the blood
stream to advance detection of cancer and treatment monitoring. In this study, the
investigators will utilize the novel technology for circulating tumor cell detection in order
to evaluate their presence in patients with lung cancer.
stream to advance detection of cancer and treatment monitoring. In this study, the
investigators will utilize the novel technology for circulating tumor cell detection in order
to evaluate their presence in patients with lung cancer.
The plan is to collect both blood and tumor samples from the patient's lung cancer in order
to validate this technology in detecting circulating tumor cells. The investigators will also
obtain a postoperative blood sample to see if there is a decrease in the overall circulating
tumor cell measurement once the tumor has been surgically removed.
to validate this technology in detecting circulating tumor cells. The investigators will also
obtain a postoperative blood sample to see if there is a decrease in the overall circulating
tumor cell measurement once the tumor has been surgically removed.
Inclusion Criteria:
- Stage IB and above non-small cell lung cancer or metastatic lung cancer
- Age >18 years old
- Willing and able to consent to study
- No prior history of neoadjuvant therapy.
Exclusion Criteria:
- Age <18 years old
- Unable to provide consent
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
